Details for Patent: 8,324,208

Which drugs does patent 8,324,208 protect, and when does it expire?

Patent 8,324,208 protects JESDUVROQ and is included in one NDA.

This patent has thirty-six patent family members in thirty-one countries.

Drugs Protected by US Patent 8,324,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		DISCN	Yes	No			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-002	Feb 1, 2023		DISCN	Yes	No			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		DISCN	Yes	No			Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No			Y	Y

International Family Members for US Patent 8,324,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061570
Australia	2007260837
Brazil	PI0713446
Canada	2655491